1 row is stored for this page
| Field | Field type | Value |
|---|
| generic | String | Fenofibrate |
| brand | String | Tricor, Lipofen, Antara, Fenoglide, Lofibra, Triglide, Trilipix (fenofibric acid) |
| structure | File | |
| classes | List of String, delimiter: , | [[:Category:Fibrates|Fibrate]] • [[:Category:Lipid-lowering_agents|Lipid-lowering agent]] • [[:Category:PPAR_alpha_agonists|PPAR-α agonist]] |
| mechanism | String | '"`UNIQ--vote-000004A9-QINU`"' Modest HDL rise; LDL effects mixed. Renally cleared; combination with statin carries elevated myopathy risk (greater for gemfibrozil than fenofibrate, but caution still warranted)'"`UNIQ--ref-000004AA-QINU`"'. |
| uses | String | '"`UNIQ--vote-000004AB-QINU`"', '"`UNIQ--vote-000004AC-QINU`"' |
| starting_dose | String | Varies by salt form and brand; e.g., Tricor 145 mg PO daily; reduce to 48 mg in renal impairment |
| preparations | String | Multiple non-bioequivalent fenofibrate and fenofibric acid formulations: 48-200 mg |
| fda_max | String | Formulation-specific (e.g., 145 mg/d Tricor, 200 mg/d Lipofen) |
| pill_id | Text | |
| routes | List of String, delimiter: , | Oral |
| onset | String | Triglyceride lowering at 4-8 weeks |
| duration | String | 24 hours |
| halflife | String | ~20 hours (fenofibric acid, the active metabolite)'"`UNIQ--ref-000004AD-QINU`"' |
| bioavailability | String | Increased with food (varies by formulation; the micronized and nanocrystal forms are less food-dependent)'"`UNIQ--ref-000004AE-QINU`"' |
| pregnancy | String | Limited data; generally avoided unless triglyceride pancreatitis risk is high.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> |
| legal | String | [[USLegal:Prescription only|Rx-only]] in US |
